Objective: We evaluated the relationship between hip and waist circumferences (HCs, WCs), waist-to-hip ratio, height, weight and body mass index (BMI) and breast cancer risk according to menopausal status of women and cancer hormone receptor status. Design: We used data from the French E3N longitudinal prospective cohort. Subjects: In the total population of 63 726 women who were analyzed, 1887 breast cancer cases were diagnosed during follow-up. Results: Among postmenopausal women, the risk of ER þ /PR þ breast cancer increased with increasing weight, BMI, and both HCs and WCs, although these two associations disappeared after adjustment for BMI. No association was seen with ERÀ/PRÀ breast cancers. Among premenopausal women, among the different factors studied, HC only (no association was observed for any of the different factors studied except for HC) was associated with an increased risk of ER þ /PR þ breast cancer after adjustment for BMI (hazard ratio (HR) ¼ 1.65; (1.04-2.62) when comparing the highest to lowest tertile; P-trend across tertiles ¼ 0.03) and of ERÀ/PRÀ breast cancer both before and after adjustment for BMI (HR ¼ 2.85 (1.33-6.13); P-trend o0.01, and HR ¼ 3.13 (1.19-8.27) P-trend ¼ 0.02, respectively). In the latter group, the association with HC was observed whatever the WC (HR ¼ 2.81 (1.18-6.70) and HR ¼ 2.79 (1.16-6.76) in women with high HC/low WC and high HC/high WC, respectively). Conclusion: The increase in risk of premenopausal breast cancer associated with large HC for both ER þ /PR þ and ERÀ/PRÀ subtypes may provide insight into a specific risk factor for premenopausal breast cancer.
Introduction
Body mass index (BMI), weight, waist (WC) and hip (HC) circumference and waist-to-hip ratio (WHR) are the most commonly used indicators for assessing the amount and distribution of adipose tissue in the body. 1, 2 Various studies and meta-analyses [3] [4] [5] [6] have already examined the link between these anthropometric measurements and breast cancer risk according to hormone receptor status, but some associations remain controversial, especially for premenopausal and estrogen-and progesterone-receptor-negative (ERÀ/PRÀ) breast cancer risk. Most premenopausal and ERÀ/PRÀ breast cancer risk factors remain unknown, possibly due to the restricted number of cases and poor statistical power in this subgroup. 7 Progress in understanding the pathophysiology, therefore allowing potential prevention strategies, is most expected as these cancers have a lower short term survival rate compared with cancers in postmenopause or with positive hormone receptors. 8 BMI is the risk factor that is most commonly investigated in the literature. Increased BMI has been convincingly associated with increased breast cancer risk in postmenopausal women, specifically ER þ tumors, and with decreased premenopausal breast cancer risk, except in Asian populations characterized by low adiposity. [3] [4] [5] [6] [9] [10] [11] However, it is still unclear as to whether there is a specific effect of abdominal obesity on breast cancer risk. 12, 13 WC has often been associated with increased breast cancer risk in postmenopausal women, but not in premenopausal women, 12, 13 although this association was often lost when adjusting for BMI, which is highly correlated with WC. [13] [14] [15] [16] In contrast, little is known about HC, although fat storage may potentially exert a differential effect on breast cancer risk. 2 Moreover, although some studies have evaluated the combined effect of HC and WC through the WHR, 13 little is known about the link between body shape and breast cancer risk. Hormonal mechanisms have been put forward as potential explanations for associations between anthropometric measures and breast cancer risk. Indeed, serum total estradiol levels have been shown to be related to BMI, with an inverse U-shape before 17, 18 and a linear increase after menopause. 12 Furthermore, the possible relationship between central obesity and breast cancer risk is consistent with a role of insulin resistance in pre-and postmenopausal women, 12, 13, 19, 20 as central obesity is a predictor of insulin resistance independently of general obesity. 13 To clarify potential associations between various anthropometric measures and breast cancer risk according to menopausal status and to the hormone receptor status of the cancer, we used data from the large French prospective E3N cohort that provided detailed information on HC, WC, WHR, height, weight and BMI.
Subjects and methods

Study cohort
The E3N cohort is made up of 98 995 women living in France and covered by a national health insurance scheme primarily involving school teachers. Participants were 40-65-years-old when they first entered the cohort between June 1990 and November 1991. At inclusion, they filled a baseline questionnaire, which contained questions on established risk factors for breast cancer, including aspects of reproductive life, menopausal status, history of benign breast disease, breast cancer in first-degree relatives and a variety of lifestyle characteristics. Follow-up questionnaires were sent out B2-3 years thereafter.
All questionnaires inquired about cancer occurrence and type, requesting addresses of physicians and permission so as to contact them. A small number of breast cancer cases were further identified from insurance files and death certificates. Pathology reports were obtained for 92.7% of incident cases. Information on ER and PR status was extracted from those reports, and invasive breast cancer cases were classified into four categories according to whether they had positive or negative receptors : ER þ /PR þ , ER þ /PRÀ, ERÀ/PR þ and ERÀ/PRÀ, plus a category for those with missing information on receptor status. Women were considered postmenopausal if they had had 12 consecutive months without menstrual periods (unless due to hysterectomy), had undergone bilateral oophorectomy, had ever used menopausal hormone therapy, or self-reported that they were postmenopausal. We defined the date of menopause as the date preceding 12 consecutive months of amenorrhea (unless due to hysterectomy and if the last menstrual period occurred before menopausal hormone therapy use); the date of bilateral oophorectomy; or, if not available, in decreasing order of priority: the self-reported date of menopause, the date when menopausal hormone therapy use began, the date when menopausal symptoms began; or, if no information was available, the date corresponding to age 47 years if menopause was artificial, and age 51 years otherwise, ages which corresponded to the median ages for artificial and natural menopause in the cohort, respectively.
Assessment of anthropometric measurements
Self-reported weight was obtained from each of the seven consecutive questionnaires considered for this study, selfreported height from the first questionnaire (sent in 1990), fourth questionnaire (sent in 1995), sixth questionnaire (sent in 2000) and seventh questionnaire (sent in 2002), and self-reported WC and HC in the fourth questionnaire (sent in 1995) and seventh questionnaire (sent in 2002). Women were asked to measure their WC and HC as indicated in a figure in the questionnaire: WC was determined as the smallest circumference between the base of the ribs and the largest point of the iliac crest, 21 whereas HC was the largest circumference at the maximum circumference of the buttocks, the subject standing with feet placed together.
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BMI was computed at each questionnaire as weight/ (height Â height) (kg m À2 ), using the closest available weight and a standardized height for all questionnaires, and WHR was computed as WC/HC. HC, WC and WHR were divided into tertiles with cutoffs of 93 and 99 cm for HC, 71 and 77 cm for WC and 0.75 and 0.80 for WHR. BMI was considered in five categories with cutoffs of 20, 22.5, 25 and 30 kg m
À2
. Women were also grouped into four categories of body shape, which combined low versus high HC (cutoff 96 cm) with low versus high WC (cutoff 75 cm).
Population of analysis
Follow-up started in 1995, the date of return of the fourth questionnaire. Responders (n ¼ 69 149) contributed personyears of follow-up until the date of cancer diagnosis, the date of the last completed questionnaire, or July 2005, date of mailing of the last questionnaire available (the eighth), whichever occurred first. We excluded women with any prevalent cancer (other than a basal cell carcinoma) (n ¼ 3897), women with no follow-up (n ¼ 782) and women with primary amenorrhea (n ¼ 22 
Statistical analysis
Cox proportional hazards regression models with age as the time-scale were used to estimate hazard ratios (HRs) and 95% confidence intervals of the risk for the four different categories of breast cancer defined by hormonal receptor status: ER þ /PR þ , ER þ /PRÀ, ERÀ/PR þ and ERÀ/PRÀ. Models were adjusted for the following variables: education level (undergraduate/graduate or postgraduate), total physical activity (MET-h/week, recorded at baseline), alcohol-free energy intake (kcal per day) and alcohol intake (g per day, estimated from the dietary questionnaire sent in 1993), smoking status (non-smoker/smoker, considered as a time-dependent variable), age at menarche (year, continuous), nulliparity (yes/no) and age at first full-term pregnancy (before/after 30 years), breastfeeding (yes/no), use of oral contraceptive (never, current use or former use stopped less than 10 years ago, former use stopped over 10 years ago, as a time-dependent variable), age at menopause (continuous, for postmenopausal women only), family history of breast cancer (time-dependent), mammography during the previous follow-up period (yes/no, time-dependent), history of benign breast disease (never/ever, time-dependent) and use of hormone replacement therapy (current/non-user, timedependent, for postmenopausal women only). They were further stratified on year of birth ([1925-1930] [1945] [1946] [1947] [1948] [1949] [1950] ). Due to the interaction between BMI and breast cancer risk (P ¼ 0.01), models were stratified on menopausal status. In additional series, models were adjusted for height (cm, time-dependent) and BMI (kg m
À2
, time-dependent). When data were missing for less than 5% of adjustment variables, we replaced missing values by the median value. When weight (and thus BMI) was missing at one questionnaire, the preceding value was considered until the next known value. We used competitive models to estimate HR pertaining to the different types of breast cancer. The w 2 -tests were computed to evaluate homogeneity between breast cancer types in the association with the main exposure variable, after adjustment for the above-mentioned confounding factors. All P-values were two tailed. All analyses were performed using SAS software, version 9.1 (SAS Institute, Inc., Cary, NC, USA).
Results
Baseline mean characteristics of the study population and their standard deviations are presented in Table 1 according to the case/non-case status. The distribution of the 1887 breast cancer cases was as follows: 1167 were ER þ /PR þ , 347 were ER þ /PRÀ, 76 were ERÀ/PR þ and 297 were ERÀ/PRÀ. Regarding ER þ /PRÀ and ERÀ/PR þ breast cancer, there was no association with any of the studied anthropometric factors; thus, results regarding these groups are available as online data supplements (Supplementary Tables 4-6 ), although we focused our analyses on ER þ /PR þ and ERÀ/PRÀ breast cancers.
HR associated with tertiles of height, weight and category of BMI are shown in Table 2 . We found no association between height and ER þ /PR þ breast cancer risk, whether at pre-or postmenopause. Weight was weakly associated with ER þ / PR þ breast cancer risk, with a borderline negative trend detected for premenopause (P ¼ 0.07) and a positive trend for postmenopause (Po0.01). We did not find any association between weight, height, BMI and ERÀ/PRÀ breast cancer risk. ). There was no association between BMI and ERÀ/PRÀ breast cancer risk at pre-or postmenopause.
We then analyzed HR associated with HC, WC, WHR and body shape in multivariate models with and without adjustment for BMI, among women with ER þ /PR þ (Table 3a) and ERÀ/PRÀ (Table 3b ) breast cancers, respectively.
There was a significant increase in ER þ /PR þ postmenopausal breast cancer risk with increasing HC and WC, which disappeared after adjustment for BMI (Table 3a) . No association was detected with WHR or body shape distribution. In premenopausal women, a positive association with HC was detected after adjustment for BMI with, in the highest tertile, a HR of 1.65 (1.04-2.62) and a positive trend across tertiles (P ¼ 0.03). No significant association between ER þ /PR þ breast cancer risk and WC, WHR or fat distribution was observed after adjustment for BMI.
Regarding ERÀ/PRÀ cancers (Table 3b) , the only significant association observed in premenopausal women concerned HC, and significance was not altered after adjusting for BMI (HR in the last tertile as compared with the first ¼ 3.13 (1.19-8.27 ); P-trend across tertiles ¼ 0.02). Associations between HC and premenopausal breast cancer were significantly different between ER þ /PR þ and ERÀ/PRÀ cancers (homogeneity w 2 -test, P ¼ 0.02) in models not adjusted for BMI; however, the test for homogeneity was no longer statistically significant after adjusting for BMI (P ¼ 0.25). The increased risk of ERÀ/PRÀ premenopausal breast cancer associated with high HC was independent of WC or BMI; in women with high HC/low WC, HR were 2.66 (1.15-6.14) and 2.81 (1.18-6.70) without and with adjustment for BMI, respectively; in women with high HC/high WC, HR were 2.44 (1.24-4.81) and 2.79 (1.16-6.76) without and with adjustment for BMI, respectively, as compared with women with low HC/low WC. An additional analysis on four subgroups of women crossing two categories of HC (cutpoint 96 cm) with two categories of BMI (cutpoint 22.7) also revealed that increases in risk in premenopausal women with high HC in the ER þ /PR þ and ERÀ/PRÀ subgroups were observed whatever the BMI of the women (data not shown).
There was no association of any anthropometric variable with postmenopausal ERÀ/PRÀ breast cancers.
Further adjustment for height as a continuous variable or as a categorical variable, or adjusting for WC and HC reciprocally, did not modify associations between HC, WC or WHR and breast cancer (data not shown).
Discussion
In this large cohort of French women, weight and BMI were associated with risk of breast cancer types having doublepositive hormone receptors, but not with any other type. Abbreviations: BMI, body mass index; HR, hazard ratio; CI, confidence interval. *Models were adjusted for the following variables: education level (undergraduate/ graduate or postgraduate), total physical activity (MET-h/ week, baseline), alcohol-free energy intake (kcal per day), alcohol intake (g per day, variables estimated from the dietary questionnaire sent in 1993), smoking status (non-smoker/smoker, time-dependent), age at menarche (year, continuous), nulliparity (yes/no) and age at first full-term pregnancy (before/after 30 years), breastfeeding (yes/no), use of oral contraceptive (never, current use or former use since less than 10 years, former use since more than 10 years, time-dependent), age at menopause (continuous, for postmenopausal women only), family history of breast cancer (timedependent), mammography during the previous follow-up period (yes/no, time-dependent), history of benign breast disease (never/ever, time-dependent), use of hormone replacement therapy (current/non-user, time-dependent, for postmenopausal women only), further stratified on year of birth ([1925-1930] Hip circumference and breast cancer risk G Fagherazzi et al Abbreviations: BMI, body mass index; HC, hip circumference; HR, hazard ratio; CI, confidence interval; WC, waist circumferences, WHR, waist-to-hip ratio. *Models were adjusted for the following variables: education level (undergraduate/graduate or postgraduate), total physical activity (MET-h/ week, baseline), alcohol-free energy intake (kcal per day), alcohol intake (g per day, variables estimated from the dietary questionnaire sent in 1993), smoking status (non-smoker/smoker, timedependent), age at menarche (year, continuous), nulliparity (yes/no) and age at first full-term pregnancy (before/after 30 years), breastfeeding (yes/no), use of oral contraceptive (never, current use or former use since less than 10 years, former use since more than 10 years, time-dependent), age at menopause (continuous, for postmenopausal women only), family history of breast cancer (time-dependent), mammography during the previous follow-up period (yes/no, time-dependent), history of benign breast disease (never/ever, time-dependent), use of hormone replacement therapy (current/non user, time-dependent, for postmenopausal women only), and height (cm, time-dependent), further stratified on year of birth ([1925-1930] Abbreviations: BMI, body mass index; HC, hip circumference; HR, hazard ratio; CI, confidence interval; WC, waist circumferences, WHR, waist-to-hip ratio. *Models were adjusted for the following variables: education level (undergraduate/graduate or postgraduate), total physical activity (MET-h/ week, baseline), alcohol-free energy intake (kcal per day), alcohol intake (g per day, variables estimated from the dietary questionnaire sent in 1993), smoking status (non-smoker/smoker, timedependent), age at menarche (year, continuous), nulliparity (yes/no) and age at first full-term pregnancy (before/after 30 years), breastfeeding (yes/no), use of oral contraceptive (never, current use or former use since less than 10 years, former use since more than 10 years, time-dependent), age at menopause (continuous, for postmenopausal women only), family history of breast cancer (time-dependent), mammography during the previous follow-up period (yes/no, time-dependent), history of benign breast disease (never/ever, time-dependent), use of hormone replacement therapy (current/non user, time-dependent, for postmenopausal women only), and height (cm, time-dependent), further stratified on year of birth ([1925-1930] 
Hip circumference and breast cancer risk G Fagherazzi et al
The effect tended toward an increase after menopause, and a decrease before. HC was associated with risk of premenopausal double-positive and double-negative breast cancers. The association was stronger with ERÀ/PRÀ tumors than with ER þ /PR þ cancers, where the risk appeared only after adjustment for BMI. Height, WC and WHR were not associated with any type of breast cancer either in pre-or postmenopause.
Height and breast cancer risk
The influence of height on breast cancer has been hypothesized to be associated with an increased risk, but evidence is limited: such an influence seemed to be restricted to postmenopausal women in one case-control study, 23 or was very weakly associated with increased breast cancer mortality risk in a pooled analysis of 38 population-based cohort studies in Asia-Pacific, 24 whatever the hormonal receptor status of the tumor. We did not observe any association between breast cancer risk and height, but the height range in our cohort was limited, with few tall women.
Overall adiposity and breast cancer risk Concerning BMI, our results were consistent with those found in the existing literature. Three reviews recently summarized results on the association between body weight or BMI and breast cancer according to receptor status.
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Suzuki et al. 5 combined results of nine cohort and 22 casecontrol studies to evaluate the impact of BMI on breast cancer defined by receptor status in pre-and postmenopausal women. They found decreased risk of premenopausal ER þ /PR þ breast cancer (HR ¼ 0.80 (0.70-0.92)), but increased risk for ER þ /PR þ postmenopausal women (HR ¼ 1.82 (1.55-2.14)) when comparing the highest vs the lowest BMI categories. They found no association in the ERÀ/PRÀ subgroup. Althuis et al. 4 in their review of the literature, Chen et al. 3 in their meta-analysis and more recently Kawai et al., 25 Parr et al. 26 and Singh et al. 27 also concluded to an increased risk of postmenopausal breast cancers associated with high BMI; this risk was more pronounced for cancers with positive receptors than those with negative receptors. It has been suggested that risk factors associated with ER þ /PR þ breast cancer may operate through exposure to estrogen and progesterone, unlike those associated with ERÀ/PRÀ breast cancer, which may involve mechanisms independent of steroid exposure. 28 Our findings of an association between BMI (negative at premenopause and positive at postmenopause) and breast cancer risk restricted to ER þ /PR þ tumors is in agreement with this hypothesis, as total serum estradiol levels have been shown to decrease in premenopausal women, but to increase in postmenopausal women with increasing BMI. 18 Furthermore, Key et al. 29 showed that the increase in postmenopausal breast cancer risk with increasing BMI was substantially reduced after adjustment for serum estrogen concentration, underlining the important role of estrogens, particularly bioavailable estrogens, in the association of breast cancer with BMI. 29 Unfortunately, estrogen levels were unavailable in our study for most subjects, making any adjustment impossible.
Central versus abdominal adiposity and breast cancer risk Most studies that specifically analyzed the link between WC or HC and breast cancer risk failed to consider the receptor status of the tumor. 13, 14, [30] [31] [32] In the EPIC cohort, Lahmann et al. 31 found that HC was the only measure significantly associated with premenopausal breast cancer risk, after accounting for BMI. In one report from a case-control study, WC and WHR were not related to breast cancer whatever the hormone receptor status of the cancer and whatever the menopausal status of the women. 33 Harvie et al. 13 concluded from a review of the literature that associations of WC and WHR with postmenopausal breast cancer risk were explained by the strong correlation between WC, WHR and BMI, a conclusion that fits with our findings. They 13 also suggested that central but not general obesity may be specifically associated with an increased risk of breast cancer among premenopausal women. Our results did not support a specific effect of central obesity in premenopausal women, but rather a risk associated with large hips.
To the best of our knowledge, a specific association of large hips with risk of premenopausal double-positive or doublenegative breast cancer has not been previously reported. Harris et al. 34 found that body fat distribution variables were associated with risk of ER-breast cancer subgroup, a result in line with our findings for HC, but not for WC and WHR where no significant association appeared for ERÀ/PRÀ subgroup.
As there has been little consistency regarding associations between anthropometry and ERÀ/PRÀ tumors, especially at premenopause, the positive association we found with HC is potentially of great interest. Despite the small number of cases, the association with HC reached statistical significance in the ERÀ/PRÀ breast cancer subgroup, a result, which needs to be confirmed by studies with larger numbers of ERÀ/PRÀ cases. The fact that large hips are associated with risk independently of WC and thus independently of an apple (larger waist than hips) or pear (larger hips than waist) shape is in favor of a specific factor associated with large hips. This could lead to new pathophysiological hypotheses regarding premenopausal breast cancer. To our knowledge, no study exists on the link between HC and breast cancer risk according to hormone receptor status. Similarly to our results for premenopause, HC was found to be a significant and independent predictor of pre-and postmenopausal breast cancer in a Chinese cohort study 35 in which, interestingly, women had a mean BMI close to the mean BMI in our study (23.6 vs. 23.3 kg m
À2
). Large HC has been inversely associated with cardiovascular disease and diabetes risk in women, [36] [37] [38] [39] and may thus reflect a proportionally 40 This relationship between HC and estradiol exposure might explain why the association between HC and ER þ /PR þ postmenopausal cancer risk disappears after adjustment for BMI, as the latter is strongly correlated with estradiol in postmenopause. 12 Conversely, this relationship might account for the increase in the association between HC and premenopausal ER þ /PR þ cancer risk after adjustment for BMI, which is inversely correlated with estradiol in premenopausal overweight women. 18 Possible mechanisms Another mechanism involved in the association between premenopausal ER þ /PR þ and ERÀ/PRÀ breast cancer risk and HC may involve leptin, one of the most important adipose tissue-derived hormone. Indeed, serum leptin levels were found to be significantly correlated with HC after controlling for fat mass. 41 Leptin stimulates estrogen biosynthesis by inducing aromatase activity and ensuing stimulation of estrogen-dependent breast cancer progression. 41 However, as many other cytokines, it also has direct mitogenic, anti-apoptotic, pro-angiogenic and pro-inflammatory effects in various cellular systems, and could thus promote estrogen-independent breast cancer development. 42 Consistently with these potential mechanisms, it has been shown in vitro that inhibition of leptin signaling results in reduced tumor activity in ER þ as well as ERÀ breast cancer cells. 43 Finally the rapid decline in circulating leptin levels rapidly decline after menopause. 44 This may contribute to the restriction to premenopausal women of the association between HC and ERÀ/PRÀ cancer risk.
Limitations
The self-report of anthropometric measurements is a potential limitation in our study. However, a validation study comparing self-reported measurements to those made by a trained nurse proved them to be very reliable: 45 except for height (r ¼ 0.56) correlation coefficients that were higher than 0.80 for all the anthropometric factors analyzed, with a maximum of 0.94 for weight. BMI correlation coefficient was 0.78. Anyway, a non-differential reporting bias would tend to reduce the true associations rather than amplify non-existing ones. Self-measurement of HC, defined as the largest circumference below the umbilicus, could lead to some heterogeneity depending on a woman's morphology. However, the validation study 45 proved that the measures were indeed highly consistent. Data on hormone receptors were taken from various laboratories and ER and PR results were scored as positive or negative using techniques and cutoffs that may not have been standardized. However, any resulting outcome misclassification is unlikely to be related to anthropometric factors, and would tend to weaken and obscure any real differences in the association of anthropometric factors with different types of breast cancer. A total of 531 women were excluded of the present analysis because hormone receptor status was unavailable. We compared these women to those with available data on hormone receptor status in terms of anthropometrical characteristics, and results were very similar, suggesting that these women do not have a specific profile.
Conclusion
Our study is the first, to our knowledge, to model the association between HC, WC, WHR, height, weight and BMI with breast cancer defined by both menopausal status and receptor status. HC, whatever the WC, is associated with an increased risk of premenopausal breast cancer of both the ER þ /PR þ and ERÀ/PRÀ subtypes, which may provide insight into a specific risk factor for premenopausal breast cancer. Moreover, in light of the obesity epidemic, the number of women with large HC may continue to increase, leading to further epidemiological studies which could confirm our findings. More specific counseling, and eventually specific preventive strategies, may then be offered to obese women or with large HC.
